From Podium To Practice – Breast Cancer ESMO Part 5
In this discussion, Dr. Wassim Mchayleh of AdventHealth introduces Dr. Sara Tolaney of Dana-Farber Cancer Institute to break down the critical differences in trial design and patient populations between ASCENT-03 and TROPION-Breast02, two pivotal antibody–drug conjugate (ADC) studies in first-line metastatic triple-negative breast cancer (mTNBC). Dr. Tolaney highlights distinctions in IO-ineligibility criteria, PD-L1 requirements, inclusion of early relapsers, crossover availability, and variations in chemotherapy control arms, explaining how these factors impact interpretation and real-world clinical decision-making. Sponsored By Gilead